MwanzoIDP • ETR
add
Biogen Inc
Bei iliyotangulia
€ 127.30
Bei za siku
€ 129.25 - € 129.65
Bei za mwaka
€ 99.00 - € 173.45
Thamani ya kampuni katika soko
21.98B USD
Wastani wa hisa zilizouzwa
716.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 2.65B | 7.33% |
Matumizi ya uendeshaji wa biashara | 783.70M | 12.02% |
Mapato halisi | 634.80M | 8.77% |
Kiwango cha faida halisi | 24.00 | 1.35% |
Mapato kwa kila hisa | 5.47 | 3.60% |
EBITDA | 1.11B | 14.61% |
Asilimia ya kodi ya mapato | 14.68% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.76B | 44.52% |
Jumla ya mali | 28.33B | 5.69% |
Jumla ya dhima | 10.70B | -2.00% |
Jumla ya hisa | 17.63B | — |
hisa zilizosalia | 146.61M | — |
Uwiano wa bei na thamani | 1.06 | — |
Faida inayotokana na mali | 8.12% | — |
Faida inayotokana mtaji | 9.57% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 634.80M | 8.77% |
Pesa kutokana na shughuli | 160.90M | -74.29% |
Pesa kutokana na uwekezaji | -57.00M | -112.22% |
Pesa kutokana na ufadhili | -11.70M | 95.23% |
Mabadiliko halisi ya pesa taslimu | 160.50M | -80.77% |
Mtiririko huru wa pesa | 223.68M | -83.73% |
Kuhusu
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1978
Makao Makuu
Tovuti
Wafanyakazi
7,605
